Low and high doses of ursolic acid ameliorate experimental autoimmune myasthenia gravis through different pathways
Authors:
- 1 April 2015
- journal article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 281, 61-67
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Characterization of peripheral blood acetylcholine receptor-binding B cells in experimental myasthenia gravisCellular Immunology, 2011
- A systematic review of population based epidemiological studies in Myasthenia GravisBMC Neurology, 2010
- CD4+ T Cells and Cytokines in the Pathogenesis of Acquired Myasthenia GravisAnnals of the New York Academy of Sciences, 2008
- Myasthenia gravis: past, present, and futureJournal of Clinical Investigation, 2006
- A dual altered peptide ligand down‐regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up‐regulation of Fas–FasL‐mediated apoptosisImmunology, 2006
- Fas‐mediated T‐cell apoptosis is impaired in patients with chronic inflammatory demyelinating polyneuropathyJournal of the Peripheral Nervous System, 2006
- Amelioration of adjuvant-induced arthritis by ursolic acid through altered Th1/Th2 cytokine productionPharmacological Research, 2006
- Breakdown of Tolerance to a Self-Peptide of Acetylcholine Receptor α-Subunit Induces Experimental Myasthenia Gravis in RatsThe Journal of Immunology, 2004
- Defective T cell Fas function in patients with multiple sclerosisNeurology, 2000
- Animal Models of Myasthenia GravisClinical Immunology, 2000